Cytokinetics financials
$65.64−0.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M | $55.8M | $26.9M | $31.5M | $13.4M | $106.4M |
| Gross profit | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M | $55.8M | $26.9M | $31.5M | $13.4M | $106.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$612.3M | -$536.2M | -$496.2M | -$324.2M | -$186.3M | -$93.9M | -$98.9M | -$88.9M | -$113.4M | $18.7M |
| Net income | -$785.0M | -$589.5M | -$526.2M | -$389.0M | -$215.3M | -$127.3M | -$121.7M | -$106.3M | -$127.8M | $16.5M |
| Net margin | −891.6% | −3191.1% | −6988.6% | −411.2% | −305.7% | −228.0% | −452.9% | −337.4% | −955.9% | 15.5% |
| Diluted EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | $-2.11 | $-1.95 | $-2.59 | $0.39 |
| EBITDA | -$602.1M | -$526.7M | -$484.3M | -$318.4M | -$184.0M | -$92.1M | -$97.6M | -$87.7M | -$111.5M | $19.4M |
| Operating cash flow | -$510.0M | -$395.9M | -$414.3M | -$299.5M | -$142.5M | $8.9M | -$90.9M | -$101.2M | -$101.8M | $37.0M |
| Free cash flow | -$534.8M | -$399.8M | -$415.7M | -$310.9M | -$191.4M | -$2.1M | -$93.5M | -$102.1M | -$104.6M | $35.4M |
| Diluted shares | 120.1M | 112.0M | 96.5M | 89.8M | 76.9M | 64.5M | 57.6M | 54.4M | 49.4M | 42.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $122.5M | $94.9M | $113.0M | $65.6M | $112.7M | $83.0M |
| Short-term investments | $759.7M | $981.2M | $501.8M | $717.0M | $359.0M | $381.1M |
| Total debt | $1.16B | $657.1M | $617.5M | $911.1M | $142.8M | $135.7M |
| Total assets | $1.42B | $1.40B | $824.3M | $1.01B | $841.3M | $533.8M |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597.5M | $420.4M |
| Shareholders' equity | -$659.6M | -$135.4M | -$386.3M | -$107.9M | $243.9M | $113.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology